Positive top-line Phase III study results of crinecerfont in CAH

San Diego, USA-based neuroscience focused biotech Neurocrine Biosciences (Nasdaq: NBIX) saw its shares rise 6.4% to $115.50 this morning, as it announced positive top-line data from the Phase III CAHtalyst Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).

The Phase III study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically-significant percent reduction in daily glucocorticoid (GC) dose versus placebo while maintaining androgen control (p-value <0.0001).

Secondary endpoints also achieved